MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
MiNK Therapeutics (NASDAQ: INKT) will report third quarter 2025 financial results before the market opens on Friday, November 14, 2025.
The company will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results, recent clinical progress and upcoming corporate milestones. MiNK recently presented late‑breaking data at the 2025 SITC Annual Meeting where its agenT-797 iNKT cell therapy showed durable immune reconstitution and signals of activity in patients with advanced solid tumors.
A live webcast and replay will be available from the company’s Events & Presentations page; dial‑in and webcast links are provided for investors.
MiNK Therapeutics (NASDAQ: INKT) riporterà i risultati finanziari del terzo trimestre 2025 prima dell'apertura del mercato venerdì 14 novembre 2025.
L'azienda terrà una teleconferenza e una webcast alle 8:30 ET nello stesso giorno per discutere i risultati, i progressi clinici recenti e i prossimi traguardi societari. MiNK ha recentemente presentato dati di forte impatto al SITC Annual Meeting 2025, dove la sua agenT-797 iNKT cell therapy ha mostrato una ricostituzione immunitaria duratura e segnali di attività nei pazienti con tumori solidi avanzati.
Una webcast dal vivo e la replica saranno disponibili dalla pagina degli Eventi e Presentazioni dell'azienda; i link di dial-in e webcast sono forniti per gli investitori.
MiNK Therapeutics (NASDAQ: INKT) reportará los resultados financieros del tercer trimestre de 2025 antes de la apertura del mercado el viernes 14 de noviembre de 2025.
La empresa organizará una conferencia telefónica y una webcast a las 8:30 a.m. ET ese mismo día para discutir los resultados, los progresos clínicos recientes y los próximos hitos corporativos. MiNK presentó recientemente datos de última hora en la Reunión Anual SITC 2025, donde su agenT-797 iNKT cell therapy mostró una reconstitución inmunitaria duradera y señales de actividad en pacientes con tumores sólidos avanzados.
Una transmisión en vivo y la repetición estarán disponibles desde la página de Eventos y Presentaciones de la empresa; se proporcionan enlaces de marcación y webcast para los inversionistas.
MiNK Therapeutics (NASDAQ: INKT)가 2025년 3분기 재무 결과를 시장 개장 전에 2025년 11월 14일 금요일에 발표합니다.
동일한 날 8:30 a.m. ET에 회사는 결과, 최근 임상 진행 상황 및 향후 기업 이정표를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 주최합니다. MiNK는 최근 2025 SITC 연례회의에서 agenT-797 iNKT 셀 치료가 지속적인 면역 재구성 및 고형 종양을 가진 진행된 환자에서의 활성 징후를 보였다고 발표했습니다.
라이브 웹캐스트와 재생은 회사의 이벤트 및 발표 페이지에서 제공되며, 투자자용 다이얼인 및 웹캐스트 링크가 제공됩니다.
MiNK Therapeutics (NASDAQ: INKT) annoncera les résultats financiers du troisième trimestre 2025 avant l’ouverture du marché le vendredi 14 novembre 2025.
L’entreprise organisera une conférence téléphonique et une webdiffusion à 8 h 30 HE ce même jour pour discuter des résultats, des progrès cliniques récents et des jalons d’entreprise à venir. MiNK a récemment présenté des données de dernière heure lors de la SITC Annual Meeting 2025, où sa agenT-797 iNKT cell therapy a montré une reconstitution immunitaire durable et des signaux d’activité chez des patients atteints de tumeurs solides avancées.
Une webdiffusion en direct et une répétition seront disponibles sur la page Événements et présentations de l’entreprise ; des liens d’accès et de webdiffusion sont fournis pour les investisseurs.
MiNK Therapeutics (NASDAQ: INKT) wird die Finanzkennzahlen für das dritte Quartal 2025 vor Börsenöffnung am Freitag, den 14. November 2025 berichten.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und Webcast veranstalten, um Ergebnisse, aktuelle klinische Fortschritte und kommende Unternehmensmeilensteine zu besprechen. MiNK hat kürzlich auf der SITC Annual Meeting 2025 Daten zu seiner agenT-797 iNKT Zelltherapie vorgestellt, die eine nachhaltige Immunrekonstruktion und Signale der Aktivität bei Patientinnen und Patienten mit fortgeschrittenen soliden Tumoren zeigen.
Übertragung im Live-Webcast und Wiederholung sind auf der Seite des Unternehmens „Events & Presentations“ verfügbar; Einwahldaten und Webcast-Links werden für Investoren bereitgestellt.
MiNK Therapeutics (NASDAQ: INKT) ستعلن عن النتائج المالية للربع الثالث من 2025 قبل افتتاح السوق يوم الجمعة 14 نوفمبر 2025.
ستعقد الشركة مكالمة مؤتمرات وبثاً مباشراً عبر الويب في 8:30 صباحاً بتوقيت شرق الولايات المتحدة في اليوم نفسه لمناقشة النتائج والتقدم السريري الأخير والمعالم المؤسسية القادمة. قدمت MiNK مؤخرًا بيانات حاسمة في اجتماع SITC السنوي 2025 حيث أظهرت علاج الخلية iNKT agenT-797 إعادة تشكيل مناعية قابلة للاستمرار وإشارات نشاط لدى مرضى أورام صلبة متقدمة.
سيكون هناك بث مباشر عبر الويب وإعادة عرض متاحة من صفحة الأحداث والعروض الخاصة بالشركة؛ يتم توفير روابط الاتصال الهاتفي والبث للمستثمرين.
- None.
- None.
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th.
The announcement follows MiNK’s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company’s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors.
MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data, and upcoming corporate milestones.
Conference Participant Dial Information
United States - New York (646) 307-1963
USA & Canada - Toll-Free (800) 715-9871
Conference ID: 3474114
Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.
Live event link: https://edge.media-server.com/mmc/p/4bufw45x
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.
Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.
Contacts
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
FAQ
When will MiNK Therapeutics (INKT) release Q3 2025 financial results?
What time is the MiNK (INKT) conference call and webcast for Q3 2025?
What clinical data did MiNK (INKT) present at SITC 2025 about agenT-797?
How can investors access the MiNK (INKT) Q3 2025 webcast and replay?
Will MiNK (INKT) discuss upcoming corporate milestones on the call?
What is agenT-797 mentioned in MiNK (INKT) materials?
